There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
From the Research
Treatment Options for Orbital Lymphoma
The treatment options for orbital lymphoma include:
- Systemic chemotherapy or immunotherapy, which is often the initial treatment modality, especially for secondary orbital lymphomas 1
- Radiation therapy, which can be used with curative intent in patients with low-grade orbital non-Hodgkin's lymphoma stages IE and IVE, and is associated with improved local recurrence-free survival (RFS) 2
- Combination of systemic therapy with local radiation treatment, which can be beneficial in some cases 1
- Surgical biopsy, which can be used to diagnose and treat orbital lymphoma, especially for localized lesions 3
- Radiotherapy alone or in association with chemotherapy or immunotherapy, which has been shown to be an effective treatment option for orbital lymphoma, with excellent local control rate and low rates of toxicity 4
Radiation Therapy
Radiation therapy is a common treatment option for orbital lymphoma, and the choice of radiation technique (e.g. external beam radiotherapy, proton beam therapy) and dose depends on the stage and histological subtype of the lymphoma. Studies have shown that:
- Radiation doses ranging from 15 to 30 Gy can achieve excellent local control 5
- Higher doses (above 35 Gy) can result in significant late complications 5
- Proton beam therapy can be used to reduce toxicity and improve local control 4
Chemotherapy
Chemotherapy can be used to treat orbital lymphoma, especially for patients with systemic disease or high-grade lymphoma. Studies have shown that:
- Cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy can be effective in treating orbital lymphoma 3
- Ifosfamide, carboplatin, etoposide chemotherapy can be used to treat systemic manifestation of orbital lymphoma 3
Treatment Outcomes
The treatment outcomes for orbital lymphoma depend on the stage, histological subtype, and treatment modality. Studies have shown that:
- Patients with stage I or II disease have better overall and cause-specific survival than patients with stage III or IV disease 5
- Local recurrence-free survival can be achieved in up to 66% of patients with stage I or II disease 5
- Systemic therapy can improve vision-related outcomes and reduce the risk of compressive optic neuropathy 1